Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness.

Tunheim G, Laake I, Robertson AH, Waalen K, Hungnes O, Naess LM, Cox RJ, Mjaaland S, Trogstad L.

Influenza Other Respir Viruses. 2019 Mar;13(2):191-200. doi: 10.1111/irv.12623. Epub 2019 Jan 1.

2.

Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007.

Norheim G, Mueller JE, Njanpop-Lafourcade BM, Delrieu I, Findlow H, Borrow R, Xie O, Nagaputra J, Ramasamy R, Dold C, Tamekloe TA, Rollier CS, Watt H, Kere AB, Næss LM, Pollard AJ.

Vaccine. 2018 Feb 28;36(10):1297-1303. doi: 10.1016/j.vaccine.2018.01.031. Epub 2018 Feb 2.

3.

Immune responses of a meningococcal A + W outer membrane vesicle (OMV) vaccine with and without aluminium hydroxide adjuvant in two different mouse strains.

Tunheim G, Arnemo M, Naess LM, Norheim G, Garcia L, Cardoso D, Mandiarote A, Gonzalez D, Sinnadurai K, Fjeldheim ÅK, Bolstad K, Rosenqvist E.

APMIS. 2016 Nov;124(11):996-1003. doi: 10.1111/apm.12589. Epub 2016 Sep 20.

PMID:
27651089
4.

Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers.

Bårnes GK, Workalemahu B, Kristiansen PA, Beyene D, Merdekios B, Fissiha P, Aseffa A, Caugant DA, Naess LM.

Scand J Immunol. 2016 Aug;84(2):118-29. doi: 10.1111/sji.12451.

5.

Heat shock protein complex vaccines induce antibodies against Neisseria meningitidis via a MyD88-independent mechanism.

Han JX, Ng GZ, Cecchini P, Chionh YT, Saeed MA, Næss LM, Joachim M, Blandford LE, Strugnell RA, Colaco CA, Sutton P.

Vaccine. 2016 Mar 29;34(14):1704-11. doi: 10.1016/j.vaccine.2016.02.001. Epub 2016 Feb 12.

PMID:
26876441
6.

Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Oftung F, Korsvold GE, Aase A, Næss LM.

Clin Vaccine Immunol. 2016 Apr 4;23(4):353-62. doi: 10.1128/CVI.00666-15. Print 2016 Apr.

7.

Development and Evaluation of a Multiplex Microsphere Assay for Quantitation of IgG and IgA Antibodies against Neisseria meningitidis Serogroup A, C, W, and Y Polysaccharides.

Bårnes GK, Kristiansen PA, Caugant DA, Næss LM.

Clin Vaccine Immunol. 2015 Jul;22(7):697-705. doi: 10.1128/CVI.00087-15. Epub 2015 Apr 29.

8.

Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.

Tunheim G, Naess LM, Acevedo R, Fjeldheim ÅK, Bolstad K, García L, Cardoso D, Aase A, Zayas C, González H, Rosenqvist E, Norheim G.

Vaccine. 2014 Nov 20;32(49):6631-8. doi: 10.1016/j.vaccine.2014.09.063.

PMID:
25305564
9.

Avidity of IgG antibodies against meningococcal serogroup a polysaccharide and correlations with bactericidal activity in sera from meningitis patients and controls from Ethiopia.

Medhane M, Tunheim G, Naess LM, Mihret W, Bedru A, Norheim G, Petros B, Aseffa A, Rosenqvist E.

Scand J Immunol. 2014 Apr;79(4):267-75. doi: 10.1111/sji.12150.

10.

Human antibody responses to pneumococcal surface protein A and capsular polysaccharides during acute and convalescent stages of invasive disease in adult patients.

Kolberg J, Aase A, Naess LM, Aaberge IS, Caugant DA.

Pathog Dis. 2014 Feb;70(1):40-50. doi: 10.1111/2049-632X.12106. Epub 2013 Nov 21.

PMID:
24151210
11.

Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.

Tunheim G, Arnemo M, Næss LM, Fjeldheim ÅK, Nome L, Bolstad K, Aase A, Mandiarote A, González H, González D, García L, Cardoso D, Norheim G, Rosenqvist E.

Vaccine. 2013 Dec 9;31(51):6097-106. doi: 10.1016/j.vaccine.2013.09.044. Epub 2013 Oct 10.

PMID:
24120679
12.

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.

Holst J, Oster P, Arnold R, Tatley MV, Næss LM, Aaberge IS, Galloway Y, McNicholas A, O'Hallahan J, Rosenqvist E, Black S.

Hum Vaccin Immunother. 2013 Jun;9(6):1241-53. doi: 10.4161/hv.24129. Epub 2013 Mar 7. Review.

13.

Meningococcal omp85 in detergent-extracted outer membrane vesicle vaccines induces high levels of non-functional antibodies in mice.

Wedege E, Lie K, Bolstad K, Weynants VE, Halstensen A, Herstad TK, Kreutzberger J, Nome L, Naess LM, Aase A.

Scand J Immunol. 2013 Jun;77(6):452-9. doi: 10.1111/sji.12051.

14.

An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt.

Norheim G, Tunheim G, Næss LM, Kristiansen PA, Caugant DA, Rosenqvist E.

Scand J Immunol. 2012 Aug;76(2):99-107. doi: 10.1111/j.1365-3083.2012.02709.x.

15.

Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine.

Bårnes GK, Naess LM, Rosenqvist E, Guerin PJ, Caugant DA; Fractional Doses Vaccine Study Group.

Scand J Immunol. 2011 Jul;74(1):87-94. doi: 10.1111/j.1365-3083.2011.02535.x.

16.

Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies.

Hellerud BC, Aase A, Herstad TK, Naess LM, Kristiansen LH, Trøseid AM, Harboe M, Lappegård KT, Brandtzaeg P, Høiby EA, Mollnes TE.

Infect Immun. 2010 Feb;78(2):802-9. doi: 10.1128/IAI.01044-09. Epub 2009 Nov 23.

17.

Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.

Guerin PJ, Naess LM, Fogg C, Rosenqvist E, Pinoges L, Bajunirwe F, Nabasumba C, Borrow R, Frøholm LO, Ghabri S, Batwala V, Twesigye R, Aaberge IS, Røttingen JA, Piola P, Caugant DA.

PLoS Negl Trop Dis. 2008;2(12):e342. doi: 10.1371/journal.pntd.0000342. Epub 2008 Dec 2.

18.

Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B.

Davenport V, Groves E, Horton RE, Hobbs CG, Guthrie T, Findlow J, Borrow R, Naess LM, Oster P, Heyderman RS, Williams NA.

J Infect Dis. 2008 Sep 1;198(5):731-40. doi: 10.1086/590669.

PMID:
18636953
19.

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nøkleby H, Rosenqvist E.

Clin Vaccine Immunol. 2007 Sep;14(9):1062-9. Epub 2007 Jul 18.

20.

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nøkleby H, Aaberge IS.

Clin Vaccine Immunol. 2006 Jul;13(7):790-6.

21.

Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.

Taha MK, Zarantonelli ML, Alonso JM, Naess LM, Holst J, Feiring B, Rosenqvist E.

Vaccine. 2007 Mar 30;25(14):2537-8. Epub 2006 Jan 20. No abstract available.

PMID:
16460845
22.

International validation of novel pyrogen tests based on human monocytoid cells.

Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, Mistry Y, Montag-Lessing T, Spreitzer I, Löschner B, van Aalderen M, Bos R, Gommer M, Nibbeling R, Werner-Felmayer G, Loitzl P, Jungi T, Brcic M, Brügger P, Frey E, Bowe G, Casado J, Coecke S, de Lange J, Mogster B, Naess LM, Aaberge IS, Wendel A, Hartung T.

J Immunol Methods. 2005 Mar;298(1-2):161-73.

PMID:
15847806
23.

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.

Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Høiby EA, Bryn K, Oster P, Costantino P, Taha MK, Alonso JM, Caugant DA, Wedege E, Aaberge IS, Rappuoli R, Rosenqvist E.

Vaccine. 2005 Mar 18;23(17-18):2202-5.

PMID:
15755595
24.

Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease.

Aase A, Naess LM, Sandin RH, Herstad TK, Oftung F, Holst J, Haugen IL, Høiby EA, Michaelsen TE.

Vaccine. 2003 May 16;21(17-18):2042-51.

PMID:
12706694
25.

Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.

Bakke H, Lie K, Haugen IL, Korsvold GE, Høiby EA, Naess LM, Holst J, Aaberge IS, Oftung F, Haneberg B.

Infect Immun. 2001 Aug;69(8):5010-5.

26.

T-cell responses against meningococcal antigens.

Næss LM, Oftung F, Aase A, Michaelsen TE, Pollard AJ.

Methods Mol Med. 2001;66:339-48. doi: 10.1385/1-59259-148-5:339.

PMID:
21336766
27.
28.

Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.

Oftung F, Naess LM, Wetzler LM, Korsvold GE, Aase A, Høiby EA, Dalseg R, Holst J, Michaelsen TE, Haneberg B.

Infect Immun. 1999 Feb;67(2):921-7.

29.

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

Haneberg B, Dalseg R, Wedege E, Høiby EA, Haugen IL, Oftung F, Andersen SR, Naess LM, Aase A, Michaelsen TE, Holst J.

Infect Immun. 1998 Apr;66(4):1334-41.

30.

Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.

Naess LM, Oftung F, Aase A, Wetzler LM, Sandin R, Michaelsen TE.

Infect Immun. 1998 Mar;66(3):959-65.

Supplemental Content

Loading ...
Support Center